The Role Intraoperative Salbutamol Inhaler in Preventing Atelectasis

NCT07591558 | Not Yet Recruiting Early Phase 1

• 1 other identifier: Apr2026/191-49
• Study Type: interventional
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

Atelectasis is considered a common complication in the perioperative period, especially following surgeries under general anesthesia. Postoperative atelectasis could occur anytime during the perioperative period from intraoperative period to 24 hours postoperative and contribute to a variety of other complications, including hypoxemia and pneumonia. In the literature, several methods were utilized to combat this phenomenon, therefore, we investigate the role of intraoperative salbutamol in reducing the incidence of atelectasis. It is well known that salbutamol could be an adjunctive bronchodilator medication used in the intraoperative anesthetic regimens.

Conditions

Atelectases, Postoperative Pulmonary; Diabete Mellitus

Keywords

atelectasis; salbutamol; pulmonary; bronchodilator

Outcome Measures

Primary Outcomes (3)

• Postoperative atelectasis (vital signs)

  All patients will undergo a thorough medical history, appropriate physical examination, and relevant investigations according to their clinical needs. Particular attention will be given to vital signs, especially pulse oximetry.

  5 months

• Postoperative atelectasis (x-ray)

  All patients will undergo a chest X-ray to investigate for atelectasis.

  5 months

• Postoperative atelectasis (blood gases)

  Postoperatively blood gases will be assessed to investigate for atelectasis. This will be done through arterial blood gases sample at 24 hours postoperative.

  5 months

Study Arms (4)

salbutamol group for diabetic patients

EXPERIMENTAL

for diabetic patients

Drug: Salbutamol (Ventolin®)

no intervention for diabetic

NO INTERVENTION

salbutamol group for non-diabetic patients

EXPERIMENTAL

for non-diabetic patients

Drug: Salbutamol (Ventolin®)

no intervention for non-diabetic patients

NO INTERVENTION

for non-diabetic patients

Interventions

Salbutamol (Ventolin®) DRUG

-4 puffs of salbutamol (each puff = 100 µg, total dose 200-400 µg)

salbutamol group for diabetic patients; salbutamol group for non-diabetic patients

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• The study will include patients aged 18-70 years
• American Society of Anesthesiologists (ASA) physical status of I or II
• Will undergo thoracic, abdominal or spinal surgery

You may not qualify if:

• cardiac conditions other than hypertension like arrhythmia
• previous cardiac surgeries and valvular heart diseases

Sponsors & Collaborators

• King Abdullah University Hospital: lead
• Jordan University of Science and Technology: collaborator

Study Sites (1)

King Abdullah University Hospital

Irbid, Jordan

Location

MeSH Terms

Conditions

Pulmonary Atelectasis; Diabetes Mellitus

Interventions

Albuterol

Condition Hierarchy (Ancestors)

Lung Diseases; Respiratory Tract Diseases; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Intervention Hierarchy (Ancestors)

Ethanolamines; Amino Alcohols; Alcohols; Organic Chemicals; Amines; Phenethylamines; Ethylamines

Central Study Contacts

Diab Bani Hani Bani Hani

CONTACT

+962798661232; dabanihani@just.edu.jo

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor of Anesthesia

Study Record Dates

• First Submitted: May 3, 2026
• First Posted: May 15, 2026
• Study Start (Estimated): June 1, 2026
• Primary Completion (Estimated): October 1, 2026
• Study Completion (Estimated): December 1, 2026
• Last Updated: May 15, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

JO (1)